Comparing of Entera Bio Ltd. (ENTX) and Amarin Corporation plc (NASDAQ:AMRN)

Entera Bio Ltd. (NASDAQ:ENTX) and Amarin Corporation plc (NASDAQ:AMRN), are influenced by contrast since they are both players in the Biotechnology. These factors are particularly influence the institutional ownership, profitability, analyst recommendations, risk, dividends, earnings and valuation of the two firms.

Earnings and Valuation

Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
Entera Bio Ltd. N/A 0.00 11.43M -1.06 0.00
Amarin Corporation plc 229.21M 29.21 116.44M -0.34 0.00

Table 1 shows top-line revenue, earnings per share and valuation of the two companies.

Profitability

Table 2 has Entera Bio Ltd. and Amarin Corporation plc’s return on assets, return on equity and net margins.

Net Margins Return on Equity Return on Assets
Entera Bio Ltd. 0.00% 0% 0%
Amarin Corporation plc -50.80% 827.8% -45.9%

Liquidity

Entera Bio Ltd.’s Current Ratio is 9.9 while its Quick Ratio is 9.9. On the competitive side is, Amarin Corporation plc which has a 2.4 Current Ratio and a 2 Quick Ratio. Entera Bio Ltd. is better positioned to pay off short and long-term obligations compared to Amarin Corporation plc.

Analyst Recommendations

The following table delivered below contains the ratings and recommendations for Entera Bio Ltd. and Amarin Corporation plc.

Sell Ratings Hold Ratings Buy Ratings Rating Score
Entera Bio Ltd. 0 0 0 0.00
Amarin Corporation plc 0 0 3 3.00

Competitively the average price target of Amarin Corporation plc is $36, which is potential 77.08% upside.

Insider and Institutional Ownership

The shares of both Entera Bio Ltd. and Amarin Corporation plc are owned by institutional investors at 9% and 49.1% respectively. Insiders owned 36.01% of Entera Bio Ltd. shares. Competitively, Amarin Corporation plc has 0.9% of it’s share owned by insiders.

Performance

In this table we show the Weekly, Monthly, Quarterly, Half Yearly, Yearly and YTD Performance of both pretenders.

Performance (W) Performance (M) Performance (Q) Performance (HY) Performance (Y) Performance (YTD)
Entera Bio Ltd. -1.79% 10% -14.89% -19.27% 0% 44.26%
Amarin Corporation plc 9.7% 22.8% 24.22% 567.39% 537.69% 57.9%

For the past year Entera Bio Ltd. has weaker performance than Amarin Corporation plc

Summary

Amarin Corporation plc beats on 6 of the 10 factors Entera Bio Ltd.

Entera Bio Ltd., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of orally delivered large molecule therapeutics for unmet medical needs. The company's lead product includes the EB612, an oral parathyroid hormone product candidate that has completed a Phase IIa clinical trial for hypoparathyroidism. It is also developing EB613 that has completed Phase I clinical trials for the treatment of osteoporosis and non-union bone fractures; and other platform modules. The company was founded in 2010 and is headquartered in Jerusalem, Israel.

Amarin Corporation plc, a biopharmaceutical company, focuses on the development and commercialization of therapeutics for the treatment of cardiovascular diseases in the United States. The companyÂ’s lead product is Vascepa, a prescription-only omega-3 fatty acid capsule, used as an adjunct to diet for reducing triglyceride levels in adult patients with severe hypertriglyceridemia. It is also involved in developing Vascepa for the treatment of patients with high triglyceride levels who are also on statin therapy for elevated low-density lipoprotein cholesterol levels. Amarin Corporation plc sells its product principally to wholesalers and specialty pharmacy providers. The company was formerly known as Ethical Holdings plc and changed its name to Amarin Corporation plc in 1999. Amarin Corporation plc was founded in 1989 and is based in Dublin, Ireland.